Characteristic | Mean ± SD (range) |
---|---|
Age, years | 55.48 ± 12.89 (26–80) |
Disease duration, years | 4.4 ± 6.9 (0–30) |
Body mass index, kg/m2 | 23.5 ± 3.2 (16.4–33.3) |
DAS28 | 3.1 ± 1.6 (0.6–7.3) |
ESR, mm/h | 26.8 ± 25.1 (2–113) |
CRP, mg/dl | 1.15 ± 2.32 (0.01–14.56) |
White blood cell count, mm3 | 7,366 ± 4,918 (3.800–17,200) |
Neutrophil, mm3 | 2,560 ± 2,287 (1,400–13,300) |
Total cholesterol, mg/dl | 175.4 ± 29.2 (126–245) |
HDL cholesterol, mg/dl | 52.6 ± 12.8 (25–92) |
LDL cholesterol, mg/dl | 107.0 ± 29.0 (42–170) |
Triglyceride, mg/dl | 128.7 ± 88.1 (35–612) |
Glucocorticoid, prednisolone, mg/day | 3.94 ± 2.94 (0–10) |
Female, n (%) | 54 (76.1) |
Rheumatoid factor positivity, n (%) | 61 (85.9) |
ACPA positivity, n (%) | 56 (78.9) |
ANA positivity, n (%) | 12 (17.0) |
2010 ACR/EULAR RA criteria, n (%) | 64 (90.1) |
Methotrexate use, n (%) | 60 (84.5) |
Sulfasalazine use, n (%) | 19 (26.8) |
Hydroxychloroquine use, n (%) | 20 (28.2) |
Leflunomide use, n (%) | 15 (21.1) |
TNF-α blockade use, n (%) | 4 (5.6) |
Disease Activity Score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HDL: high-density lipoprotein; LDL: low-density lipoprotein; ACPA: anticitrullinated protein antibody; ANA: antinuclear antibody; ACR/EULAR: American College of Rheumatology/European League Against Rheumatism; TNF: tumor necrosis factor.